Rafael Paez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rafael Paez has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Fabien Maldonado
Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
25 shared publications - Eric L. Grogan
Vanderbilt University Medical Center, Nashville, Tennessee
14 shared publications - Michael Nolan Kammer
Institut de recherche en informatique de Toulouse, Université Toulouse Capitole, Toulouse, France
13 shared publications - Stephen A. Deppen
Vanderbilt University Medical Center, Nashville, Tennessee
10 shared publications - Timothy A. Khalil
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
9 shared publications - Anna E. Baron
15Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado
8 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) of individual biomarkers compared to the combined 4-marker model in Train+Test.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) of individual biomarkers compared to the combined 4-marker model in Train+Test.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Distribution of biomarker levels for benign and malignant pulmonary nodules in the Train (A, n=371, 54% malignant) and Test (B, n=166, 44% malignant) cohorts. Brackets show the corresponding p value statistic for the t-test by biomarker.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Distribution of biomarker levels for benign and malignant pulmonary nodules in the Train (A, n=371, 54% malignant) and Test (B, n=166, 44% malignant) cohorts. Brackets show the corresponding p value statistic for the t-test by biomarker.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort composition by participating EDRN site.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort composition by participating EDRN site.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) and the sensitivity and specificity for the categorical thresholds (e.g., positive cutoffs) of each biomarker as given by the Youden’s Index test. Values are shown with their associated 95% confidence interval given in parentheses.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) and the sensitivity and specificity for the categorical thresholds (e.g., positive cutoffs) of each biomarker as given by the Youden’s Index test. Values are shown with their associated 95% confidence interval given in parentheses.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort demographic data. ‘COPD’ = chronic obstructive pulmonary disease. ‘Lung carcinogen exposure’ defined as >8hr/wk. of exposure to a known pulmonary carcinogen for at least 1 yr.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort demographic data. ‘COPD’ = chronic obstructive pulmonary disease. ‘Lung carcinogen exposure’ defined as >8hr/wk. of exposure to a known pulmonary carcinogen for at least 1 yr.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Study flow diagram of the process for prospective specimen collection on the internal training, external testing, and external validation cohorts, in addition to the subsequent biomarker measurement and analysis.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Study flow diagram of the process for prospective specimen collection on the internal training, external testing, and external validation cohorts, in addition to the subsequent biomarker measurement and analysis.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Background: Lung cancer remains the leading cause of cancer mortality, yet blood-based biomarkers are not routinely used in diagnosis. This study evaluated four commercial blood protein assays, originally validated for other indications, in indeterminate pulmonary nodules (IPN). Methods: Using a prospective specimen collection, retrospective blinded evaluation design, samples were collected from patients with screening-detected, incidental, or symptomatic IPNs. Cytokeratin 19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and human epididymis protein 4 (HE-4) concentrations were quantified on commercial immunoassays. Logistic regression models were developed using internal training (Train), external testing (Test), and combined reestimation (Train + Test) cohorts and externally validated in an outcome-blinded multicenter cohort (Lung Team Project-2, LTP-2). Results: This study included 816 patients: 371 in Train, 166 in Test, and 279 in LTP-2. Malignancy rates were 54%, 44%, and 64%, respectively. In Train + Test, the area under the receiver operating curve (AUC) for lung cancer was 0.60 (95% confidence interval, 0.56–0.65) for CYFRA 21-1, 0.62 (0.58–0.67) for CEA, 0.60 (0.55–0.65) for CA-125, and 0.65 (0.60–0.70) for HE-4. In LTP-2, AUCs were 0.63 (0.56–0.70), 0.64 (0.57–0.70), 0.48 (0.40–0.55), and 0.61 (0.54–0.68), respectively. Combining all four biomarkers yielded an AUC of 0.70 (0.65–0.74) in Train + Test and 0.61 (0.54–0.68) in LTP-2. Conclusions: In the first biomarker study reporting external validation in LTP-2, CYFRA 21-1, CEA, CA-125, and HE-4 demonstrated diagnostic value in IPNs. Impact: By leveraging commercial assays, this study highlights opportunities to enhance lung cancer risk stratification using widely available diagnostics that could be rapidly integrated into clinical workflows.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Background: Lung cancer remains the leading cause of cancer mortality, yet blood-based biomarkers are not routinely used in diagnosis. This study evaluated four commercial blood protein assays, originally validated for other indications, in indeterminate pulmonary nodules (IPN). Methods: Using a prospective specimen collection, retrospective blinded evaluation design, samples were collected from patients with screening-detected, incidental, or symptomatic IPNs. Cytokeratin 19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and human epididymis protein 4 (HE-4) concentrations were quantified on commercial immunoassays. Logistic regression models were developed using internal training (Train), external testing (Test), and combined reestimation (Train + Test) cohorts and externally validated in an outcome-blinded multicenter cohort (Lung Team Project-2, LTP-2). Results: This study included 816 patients: 371 in Train, 166 in Test, and 279 in LTP-2. Malignancy rates were 54%, 44%, and 64%, respectively. In Train + Test, the area under the receiver operating curve (AUC) for lung cancer was 0.60 (95% confidence interval, 0.56–0.65) for CYFRA 21-1, 0.62 (0.58–0.67) for CEA, 0.60 (0.55–0.65) for CA-125, and 0.65 (0.60–0.70) for HE-4. In LTP-2, AUCs were 0.63 (0.56–0.70), 0.64 (0.57–0.70), 0.48 (0.40–0.55), and 0.61 (0.54–0.68), respectively. Combining all four biomarkers yielded an AUC of 0.70 (0.65–0.74) in Train + Test and 0.61 (0.54–0.68) in LTP-2. Conclusions: In the first biomarker study reporting external validation in LTP-2, CYFRA 21-1, CEA, CA-125, and HE-4 demonstrated diagnostic value in IPNs. Impact: By leveraging commercial assays, this study highlights opportunities to enhance lung cancer risk stratification using widely available diagnostics that could be rapidly integrated into clinical workflows.
- Open Access
- 12 May 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial
Millions of lung nodules are detected every year during routine computed tomography imaging. While most are benign, some represent early-stage lung cancer
- 12 May 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessAssessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial
Millions of lung nodules are detected every year during routine computed tomography imaging. While most are benign, some represent early-stage lung cancer
- Open Access
- 3 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0327611
Robotic versus electromagnetic bronchoscopy for pulmonary leslon assessment using integrated intraprocedural imaging: Study protocol for the reliant 2 trial
Background: Robotic assisted bronchoscopy (RAB) and electromagnetic navigational bronchoscopy (ENB) are two approaches to biopsy peripheral pulmonary lesions (PPLs). A recently completed cluster randomized controlled trial, RELIANT (NCT05705544), showed no difference in diagnostic yield between these two modalities. The ENB platform used in RELIANT included integrated digital tomosynthesis, allowing for real-time assessment of PPL location for more precise targeting at the time of biopsy. RAB has since been integrated with cone beam computed tomography (CBCT) to accomplish the same intraprocedural correction. It is unclear if the diagnostic yield of RAB with integrated CBCT (RAB-CBCT) is superior to ENB with integrated digital tomosynthesis (ENB-DT). Methods: R obotic versus E lectromagnetic Bronchoscopy for Pulmonary L es I on A ssessme NT using integrated intraprocedural imaging (RELIANT 2) is an investigator-initiated, multicenter, open label, superiority, cluster randomized trial. At each participating institution, procedural rooms are randomly assigned to either RAB-CBCT or ENB-DT, with each procedure room-day considered a cluster. All adult patients undergoing navigational bronchoscopy for evaluation of PPL(s) are eligible. Allocation is concealed from schedulers, proceduralists, and patients until the morning of procedure when each room is randomized to a platform. The primary endpoint is the diagnostic yield, defined as the proportion of cases yielding a specific benign or malignant diagnosis per current ATS/ACCP definition. Secondary and safety endpoints include procedure duration and procedural complications. Enrollment began on November 11, 2024 and is expected to enroll approximately 440 patients in 220 clusters. Discussion: RELIANT 2 is an ongoing cluster randomized trial comparing the diagnostic yield of RAB-CBCT to that of ENB-DT in patients undergoing bronchoscopy to biopsy PPLs. This trial will help address some of the limitations of the recently published RELIANT trial. Trial registration The trial was registered in ClinicalTrials.gov (NCT06654271) on October 21, 2024, prior to patient enrollment.
- 3 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0327611
Open AccessRobotic versus electromagnetic bronchoscopy for pulmonary leslon assessment using integrated intraprocedural imaging: Study protocol for the reliant 2 trial
Background: Robotic assisted bronchoscopy (RAB) and electromagnetic navigational bronchoscopy (ENB) are two approaches to biopsy peripheral pulmonary lesions (PPLs). A recently completed cluster randomized controlled trial, RELIANT (NCT05705544), showed no difference in diagnostic yield between these two modalities. The ENB platform used in RELIANT included integrated digital tomosynthesis, allowing for real-time assessment of PPL location for more precise targeting at the time of biopsy. RAB has since been integrated with cone beam computed tomography (CBCT) to accomplish the same intraprocedural correction. It is unclear if the diagnostic yield of RAB with integrated CBCT (RAB-CBCT) is superior to ENB with integrated digital tomosynthesis (ENB-DT). Methods: R obotic versus E lectromagnetic Bronchoscopy for Pulmonary L es I on A ssessme NT using integrated intraprocedural imaging (RELIANT 2) is an investigator-initiated, multicenter, open label, superiority, cluster randomized trial. At each participating institution, procedural rooms are randomly assigned to either RAB-CBCT or ENB-DT, with each procedure room-day considered a cluster. All adult patients undergoing navigational bronchoscopy for evaluation of PPL(s) are eligible. Allocation is concealed from schedulers, proceduralists, and patients until the morning of procedure when each room is randomized to a platform. The primary endpoint is the diagnostic yield, defined as the proportion of cases yielding a specific benign or malignant diagnosis per current ATS/ACCP definition. Secondary and safety endpoints include procedure duration and procedural complications. Enrollment began on November 11, 2024 and is expected to enroll approximately 440 patients in 220 clusters. Discussion: RELIANT 2 is an ongoing cluster randomized trial comparing the diagnostic yield of RAB-CBCT to that of ENB-DT in patients undergoing bronchoscopy to biopsy PPLs. This trial will help address some of the limitations of the recently published RELIANT trial. Trial registration The trial was registered in ClinicalTrials.gov (NCT06654271) on October 21, 2024, prior to patient enrollment.